BlackRock Fund Advisors’s Lipocine LPCN Stock Holding History

BlackRock Fund Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.98M	Buy	31,653 +4,265	+16%	+$270K	﹤0.01%	3166
2016 Q3	$2.08M	Buy	27,388 +1,907	+7%	+$118K	﹤0.01%	3151
2016 Q2	$1.32M	Buy	25,481 +23,389	+1,118%	+$3.62M	﹤0.01%	3240
2016 Q1	$361K	Sell	2,092 -160	-7%	-$27.3K	﹤0.01%	3294
2015 Q4	$495K	Buy	2,252 +99	+5%	+$20.8K	﹤0.01%	3288
2015 Q3	$433K	Sell	2,153 -261	-11%	-$60.4K	﹤0.01%	3256
2015 Q2	$352K	Buy	2,414 +722	+43%	+$89.6K	﹤0.01%	3307
2015 Q1	$198K	Buy	1,692 +786	+87%	+$85.5K	﹤0.01%	3486
2014 Q4	$81K	Buy	+906	New	+$76.5K	﹤0.01%	3641

Other funds holding LPCN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Fund Advisors's LPCN Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Lipocine (LPCN) stake by 16% in Q4 2016, buying an estimated $270K and bringing the position to 31,653 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3166.

BlackRock Fund Advisors first reported a position in LPCN in Q4 2014 and has held it in 9 quarters since. The position peaked at $2.08M in Q3 2016. 58 funds tracked by Wall St. Rank hold LPCN as of Q4 2016.

BlackRock Fund Advisors held 31,653 shares of Lipocine worth $1.98M as of Q4 2016.
BlackRock Fund Advisors bought 4,265 Lipocine shares in Q4 2016, an estimated $270K.
Lipocine made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3166 holding.
BlackRock Fund Advisors first reported a position in Lipocine in Q4 2014 and has held it in 9 quarters since.
BlackRock Fund Advisors's Lipocine position peaked at $2.08M in Q3 2016.
58 funds tracked by Wall St. Rank held Lipocine as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.